Afternoon SPAC News Roundup: March 25, 2024
Deals and Funding Keen Vision (NASDAQ:KVAC) has entered into a non-binding letter of intent with an unnamed biopharmaceutical company based in Boston with ongoing clinical trials. This allows Keen Vision to activate an automatic six-month extension, which will push its transaction deadline to October 27. Andretti (NYSE:WNNR) has signed a non-redemption agreement with Sandia Investment
Read More